OBJECTIVES: The use of stereotactic body radiotherapy (SBRT) to treat ultra-central lung tumours remains more controversial than for peripheral and central tumours. Our objective was to assess toxicities, local control (LC) rate and survival data in patients with ultra-central lung tumours treated with SBRT. METHODS: We conducted a retrospective and monocentric study about 74 patients with an ultra-central lung tumour, consecutively treated between 2012 and 2018. Ultra-central tumours were defined as tumours whose planning target volume overlapped one of the following organs at risk (OARs): the trachea, right and left main bronchi, intermediate bronchus, lobe bronchi, oesophagus, heart. RESULTS: Median follow-up was 25 months. Two patients (2.7%) showed Grade 3 toxicity. No Grade 4 or 5 toxicity was observed. 11% of patients experienced primary local relapse. LC rate was 96.7% at 1 year and 87.6% at 2 years. Median progression free survival was 12 months. Median overall survival was 31 months. CONCLUSION: SBRT for ultra-central tumours remains safe and effective as long as protecting organs at risk is treatment-planning priority. ADVANCES IN KNOWLEDGE: The present study is one of the rare to describe exclusively ultra-central tumours through real-life observational case reports. Globally, literature analysis reveals a large heterogeneity in ultra-central lung tumours definition, prescribed dose, number of fractions. In our study, patients treated with SBRT for ultra-central lung tumours experienced few Grade 3 toxicities (2.7%) and no Grade 4 or 5 toxicities, due to the highest compliance with dose constraints to OARs. LC remained efficient.
OBJECTIVES: The use of stereotactic body radiotherapy (SBRT) to treat ultra-central lung tumours remains more controversial than for peripheral and central tumours. Our objective was to assess toxicities, local control (LC) rate and survival data in patients with ultra-central lung tumours treated with SBRT. METHODS: We conducted a retrospective and monocentric study about 74 patients with an ultra-central lung tumour, consecutively treated between 2012 and 2018. Ultra-central tumours were defined as tumours whose planning target volume overlapped one of the following organs at risk (OARs): the trachea, right and left main bronchi, intermediate bronchus, lobe bronchi, oesophagus, heart. RESULTS: Median follow-up was 25 months. Two patients (2.7%) showed Grade 3 toxicity. No Grade 4 or 5 toxicity was observed. 11% of patients experienced primary local relapse. LC rate was 96.7% at 1 year and 87.6% at 2 years. Median progression free survival was 12 months. Median overall survival was 31 months. CONCLUSION: SBRT for ultra-central tumours remains safe and effective as long as protecting organs at risk is treatment-planning priority. ADVANCES IN KNOWLEDGE: The present study is one of the rare to describe exclusively ultra-central tumours through real-life observational case reports. Globally, literature analysis reveals a large heterogeneity in ultra-central lung tumours definition, prescribed dose, number of fractions. In our study, patients treated with SBRT for ultra-central lung tumours experienced few Grade 3 toxicities (2.7%) and no Grade 4 or 5 toxicities, due to the highest compliance with dose constraints to OARs. LC remained efficient.
Authors: Susan L Tucker; Zhongxing Liao; Jeffrey Dinh; Shelly X Bian; Radhe Mohan; Mary K Martel; David R Grosshans Journal: Acta Oncol Date: 2013-08-30 Impact factor: 4.089
Authors: Chunyu Wang; Andreas Rimner; Daphna Y Gelblum; Jessica Flynn; Andrew Jackson; Ellen Yorke; Abraham J Wu Journal: JAMA Oncol Date: 2019-05-01 Impact factor: 31.777
Authors: Aadel A Chaudhuri; Chad Tang; Michael S Binkley; Michelle Jin; Jacob F Wynne; Rie von Eyben; Wendy Y Hara; Nicholas Trakul; Billy W Loo; Maximilian Diehn Journal: Lung Cancer Date: 2015-05-04 Impact factor: 5.705
Authors: Chunyu Wang; Andreas Rimner; Daphna Y Gelblum; Rosalind Dick-Godfrey; Dominique McKnight; Danielle Torres; Jessica Flynn; Zhigang Zhang; Baho Sidiqi; Andrew Jackson; Ellen Yorke; Abraham J Wu Journal: Lung Cancer Date: 2020-07-08 Impact factor: 5.705
Authors: Dan Yang; Jianing Cui; Jun Zhao; Jing You; Rong Yu; Huiming Yu; Leilei Jiang; Dongming Li; Bo Xu; Anhui Shi Journal: Thorac Cancer Date: 2020-02-03 Impact factor: 3.500